EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Increasing recognition of statin-associated anti-HMGCR antibody–positive autoimmune myopathy: a single-center retrospective study

Mikko Mali, Laura Pirilä, Manu Jokela, Tero Pääkkö, Markku Mali

Clinical Rheumatology · 2026-06 · 45 (6) · 3517-3524

DOI: 10.1007/s10067-026-08136-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Rheumatology, online erschienen am 29.04.2026. Verfasst von Mikko Mali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Oulu University, Oulu, Finland. Hauptthemen laut MEDLINE: Autoantibodies, Autoimmune Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Muscular Diseases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Turku.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The use of statins, which are inhibitors of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) enzyme, may in rare cases be associated with immune-mediated necrotizing myopathy. This condition is characterized by the presence of autoantibodies directed against the HMGCR enzyme. Previously considered very rare, the incidence of this myopathy diagnosis has markedly increased in our rheumatology unit over the past years.

Methods

We conducted a retrospective analysis of 13 patients diagnosed with statin-associated anti-HMGCR antibody (Ab)-positive immune-mediated necrotizing myopathy (anti-HMGCR-IMNM) over the 5-year period (June 2020–May 2025) at the Turku University Hospital’s rheumatology department serving 490,000 inhabitants.

Results

Patients presented with elevated creatine kinase (CK) levels, positive anti-HMGCR-Ab, proximal muscle weakness, and the initial symptom was usually difficulty walking. No other myositis autoantibodies were detected and extra-myopathic symptoms were rare. Most patients responded to immunosuppressive therapy including glucocorticoids, methotrexate or azathioprine, and rituximab with a more severe disease course. Disease severity ranged from mild to fatal. The incidence of statin-associated anti-HMGCR-IMNM was 5.3 cases per million per year, approximately 2.75 per 100,000 statin users per year, higher than previously reported.

Conclusion

Statin-associated anti-HMGCR-IMNM is a rare but increasingly recognized condition requiring early diagnosis and immunosuppressive treatment. The clinical presentation is highly variable. Treatment and its intensity must be tailored individually, taking into account the patient’s comorbidities and treatment related risks. Key Points • Anti-HMGCR antibody–positive immune-mediated necrotizing myopathy (anti-HMGCR-IMNM) may be triggered by statins, one of the most commonly prescribed classes of medications. Because delayed diagnosis may lead to significant morbidity, it is important that clinicians are familiar with this rare myopathic disorder. • Previously, statin-associated anti-HMGCR-IMNM was considered a very rare diagnosis. However, the incidence of this diagnosis appears to have increased markedly over recent years. • The apparent increase in diagnoses may be attributable to the growing use of statins; additionally, improved recognition and awareness of the disease may also partially explain this rise. • Rituximab may be an alternative in selected cases where the disease course is neither rapidly progressive nor life-threatening, although further research is needed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AutoantibodiesAutoimmune DiseasesHydroxymethylglutaryl-CoA Reductase InhibitorsMuscular DiseasesHydroxymethylglutaryl CoA ReductasesHumansRetrospective StudiesFemaleMaleMiddle AgedAgedImmunosuppressive AgentsMyositis

Stichwörter der Autor:innen

Anti-HMGCR-AbAutoimmune diseasesAutoimmune myopathyMyositisRituximab

Substanzen

AutoantibodiesHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl CoA ReductasesHMGCR protein, humanImmunosuppressive Agents

Autor:innen und Institutionen

  • Faculty of Medicine, Oulu University, Oulu, Finland.
  • Department of Rheumatology, Turku University Hospital, University of Turku, PO Box 52, Turku, 20521, Finland.
  • Department of Neurology, Neurocenter, Turku University Hospital, University of Turku, Turku, Finland.
  • Department of Neurology, Neuromuscular Center, Tampere University Hospital, Tampere, Finland.
  • Department of Rheumatology, Oulu University Hospital, Oulu, Finland.
  • Department of Rheumatology, Turku University Hospital, University of Turku, PO Box 52, Turku, 20521, Finland. markku.mali@varha.fi.

Förderung

  • University of Turku

Zitieren

APA

Mali, M., Pirilä, L., Jokela, M., Pääkkö, T., & Mali, M. (2026). Increasing recognition of statin-associated anti-HMGCR antibody–positive autoimmune myopathy: a single-center retrospective study. Clinical Rheumatology, 45(6), 3517-3524. https://doi.org/10.1007/s10067-026-08136-5

Vancouver

Mali M, Pirilä L, Jokela M, Pääkkö T, Mali M. Increasing recognition of statin-associated anti-HMGCR antibody–positive autoimmune myopathy: a single-center retrospective study. Clinical Rheumatology. 2026;45(6):3517-3524. doi:10.1007/s10067-026-08136-5

BibTeX
@article{Mali2026,
  author = {Mali, Mikko and Pirilä, Laura and Jokela, Manu and Pääkkö, Tero and Mali, Markku},
  title = {Increasing recognition of statin-associated anti-HMGCR antibody–positive autoimmune myopathy: a single-center retrospective study},
  journal = {Clinical Rheumatology},
  year = {2026},
  volume = {45},
  number = {6},
  pages = {3517--3524},
  doi = {10.1007/s10067-026-08136-5}
}
Kostenlos starten →